JP2022532187A - 腎保護物質としてのパラアミノ馬尿酸(pah) - Google Patents
腎保護物質としてのパラアミノ馬尿酸(pah) Download PDFInfo
- Publication number
- JP2022532187A JP2022532187A JP2021566582A JP2021566582A JP2022532187A JP 2022532187 A JP2022532187 A JP 2022532187A JP 2021566582 A JP2021566582 A JP 2021566582A JP 2021566582 A JP2021566582 A JP 2021566582A JP 2022532187 A JP2022532187 A JP 2022532187A
- Authority
- JP
- Japan
- Prior art keywords
- pah
- radiolabeled
- pharmaceutically acceptable
- acceptable salt
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HSMNQINEKMPTIC-UHFFFAOYSA-N N-(4-aminobenzoyl)glycine Chemical compound NC1=CC=C(C(=O)NCC(O)=O)C=C1 HSMNQINEKMPTIC-UHFFFAOYSA-N 0.000 title claims abstract description 231
- 239000000126 substance Substances 0.000 title claims description 18
- 230000001681 protective effect Effects 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 138
- 150000003839 salts Chemical class 0.000 claims abstract description 118
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 100
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 95
- 230000000694 effects Effects 0.000 claims abstract description 89
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 61
- 230000003589 nefrotoxic effect Effects 0.000 claims abstract description 53
- 231100000381 nephrotoxic Toxicity 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 49
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 239000003085 diluting agent Substances 0.000 claims abstract description 7
- 239000002738 chelating agent Substances 0.000 claims description 76
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 51
- 239000003814 drug Substances 0.000 claims description 49
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 46
- 239000012217 radiopharmaceutical Substances 0.000 claims description 46
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 46
- 239000011734 sodium Substances 0.000 claims description 42
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 40
- 229910052708 sodium Inorganic materials 0.000 claims description 40
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 39
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 32
- 230000037396 body weight Effects 0.000 claims description 29
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 238000002059 diagnostic imaging Methods 0.000 claims description 27
- 229960002700 octreotide Drugs 0.000 claims description 26
- 230000002285 radioactive effect Effects 0.000 claims description 23
- 229960000304 folic acid Drugs 0.000 claims description 22
- 239000011724 folic acid Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 20
- -1 Sargastrin Chemical compound 0.000 claims description 19
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 18
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 18
- 235000019152 folic acid Nutrition 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 108010044426 integrins Proteins 0.000 claims description 14
- 102000006495 integrins Human genes 0.000 claims description 14
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 13
- 238000003745 diagnosis Methods 0.000 claims description 12
- 102000009027 Albumins Human genes 0.000 claims description 11
- 108010088751 Albumins Proteins 0.000 claims description 11
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 11
- 108010010803 Gelatin Proteins 0.000 claims description 11
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 11
- 239000008273 gelatin Substances 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 11
- 235000019322 gelatine Nutrition 0.000 claims description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims description 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 10
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 10
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 10
- QJUIUFGOTBRHKP-LQJZCPKCSA-N (2s)-2-[[(1s)-1-carboxy-5-[6-[3-[3-[[2-[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl-(carboxymethyl)amino]ethyl-(carboxymethyl)amino]methyl]-4-hydroxyphenyl]propanoylamino]hexanoylamino]pentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)CCCCCNC(=O)CCC1=CC=C(O)C(CN(CCN(CC(O)=O)CC=2C(=CC=C(CCC(O)=O)C=2)O)CC(O)=O)=C1 QJUIUFGOTBRHKP-LQJZCPKCSA-N 0.000 claims description 9
- FQIHLPGWBOBPSG-UHFFFAOYSA-N 2-[4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetamide Chemical compound NC(=O)CN1CCN(CC(N)=O)CCN(CC(N)=O)CCN(CC(N)=O)CC1 FQIHLPGWBOBPSG-UHFFFAOYSA-N 0.000 claims description 9
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 claims description 9
- 229960001097 amifostine Drugs 0.000 claims description 9
- 239000002287 radioligand Substances 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 8
- 150000003384 small molecules Chemical class 0.000 claims description 8
- 229940116269 uric acid Drugs 0.000 claims description 8
- LHCIROHUTQLZCZ-UHFFFAOYSA-N 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-n-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide Chemical compound O=C1NC(CC=2C=CC(O)=CC=2)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C(=O)NC(CO)C(O)C)CSSCC1NC(=O)C(N)CC1=CC=CC=C1 LHCIROHUTQLZCZ-UHFFFAOYSA-N 0.000 claims description 7
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 claims description 7
- 108700014849 3-Tyr-octreotide Proteins 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical class C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 claims description 6
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 6
- ACHQFNGCBWWVRR-UHFFFAOYSA-N NOPO Chemical compound NOPO ACHQFNGCBWWVRR-UHFFFAOYSA-N 0.000 claims description 6
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 claims description 6
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 230000002988 nephrogenic effect Effects 0.000 claims description 5
- LWMCCPFUJVEMPC-UHFFFAOYSA-N [Na].NC(C(=O)O)NC(=O)C1=CC=CC=C1 Chemical compound [Na].NC(C(=O)O)NC(=O)C1=CC=CC=C1 LWMCCPFUJVEMPC-UHFFFAOYSA-N 0.000 claims description 3
- 230000000536 complexating effect Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 74
- 210000003734 kidney Anatomy 0.000 description 51
- 206010028980 Neoplasm Diseases 0.000 description 45
- 239000011780 sodium chloride Substances 0.000 description 38
- 239000007924 injection Substances 0.000 description 35
- 238000002347 injection Methods 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 33
- 229940024606 amino acid Drugs 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- RZHKDBRREKOZEW-AAXZNHDCSA-N 2-[4-[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-4-[[(2r,3r)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl] Chemical compound C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)NC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1)C1=CC=CC=C1 RZHKDBRREKOZEW-AAXZNHDCSA-N 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 21
- 108700038672 Edotreotide Proteins 0.000 description 20
- 238000001802 infusion Methods 0.000 description 20
- 230000008685 targeting Effects 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 16
- 238000003384 imaging method Methods 0.000 description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 15
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 15
- 231100000417 nephrotoxicity Toxicity 0.000 description 15
- 210000000056 organ Anatomy 0.000 description 15
- 239000004472 Lysine Substances 0.000 description 14
- 206010029155 Nephropathy toxic Diseases 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000007694 nephrotoxicity Effects 0.000 description 13
- 239000004475 Arginine Substances 0.000 description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 12
- 229960003121 arginine Drugs 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 210000005239 tubule Anatomy 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 108010078791 Carrier Proteins Proteins 0.000 description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 10
- 229960003081 probenecid Drugs 0.000 description 10
- 208000009304 Acute Kidney Injury Diseases 0.000 description 9
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 108050001286 Somatostatin Receptor Proteins 0.000 description 9
- 102000011096 Somatostatin receptor Human genes 0.000 description 9
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 8
- 102100036519 Gastrin-releasing peptide Human genes 0.000 description 8
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 8
- 229960004316 cisplatin Drugs 0.000 description 8
- 229940039227 diagnostic agent Drugs 0.000 description 8
- 239000000032 diagnostic agent Substances 0.000 description 8
- 208000017169 kidney disease Diseases 0.000 description 8
- 229960003330 pentetic acid Drugs 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- KOUZWQLNUJWNIA-UHFFFAOYSA-N 2-hydrazinylpyridine-3-carboxamide Chemical compound NNC1=NC=CC=C1C(N)=O KOUZWQLNUJWNIA-UHFFFAOYSA-N 0.000 description 7
- 101000591385 Homo sapiens Neurotensin receptor type 1 Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102100033986 Neurotensin receptor type 1 Human genes 0.000 description 7
- 108010016076 Octreotide Proteins 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 201000011040 acute kidney failure Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 201000011519 neuroendocrine tumor Diseases 0.000 description 7
- 238000002600 positron emission tomography Methods 0.000 description 7
- 238000000163 radioactive labelling Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 6
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 6
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 6
- 208000033626 Renal failure acute Diseases 0.000 description 6
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 208000002682 Hyperkalemia Diseases 0.000 description 5
- YQMWQSMYVPLYDI-UHFFFAOYSA-N alpha-Isoaphyllin Natural products C12CCCCN2C(=O)C2C3CCCCN3CC1C2 YQMWQSMYVPLYDI-UHFFFAOYSA-N 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 description 5
- 150000002891 organic anions Chemical class 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 210000000512 proximal kidney tubule Anatomy 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 101800003906 Substance P Proteins 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229960004567 aminohippuric acid Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 206010022498 insulinoma Diseases 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical group C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 3
- LGPOVIJRCHASEQ-TWMOUGLCSA-K 2-[4-[2-[[(2S)-1-[[(4R,7S,10S,13R,16S,19S)-10-(4-aminobutyl)-4-[[(2R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]carbamoyl]-13-[[4-(carbamoylamino)phenyl]methyl]-16-[[4-[[(4S)-2,6-dioxo-1,3-diazinane-4-carbonyl]amino]phenyl]methyl]-7-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-3-(4-chlorophenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate lutetium-177(3+) Chemical compound [177Lu+3].C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2ccc(NC(N)=O)cc2)NC(=O)[C@H](Cc2ccc(NC(=O)[C@@H]3CC(=O)NC(=O)N3)cc2)NC(=O)[C@@H](CSSC[C@H](NC1=O)C(=O)N[C@H](Cc1ccc(O)cc1)C(N)=O)NC(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 LGPOVIJRCHASEQ-TWMOUGLCSA-K 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000010444 Acidosis Diseases 0.000 description 3
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 3
- 108010051479 Bombesin Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 208000013038 Hypocalcemia Diseases 0.000 description 3
- 206010021027 Hypomagnesaemia Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 102000005157 Somatostatin Human genes 0.000 description 3
- 108010056088 Somatostatin Proteins 0.000 description 3
- 102400000096 Substance P Human genes 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108010062796 arginyllysine Proteins 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 108020005243 folate receptor Proteins 0.000 description 3
- 102000006815 folate receptor Human genes 0.000 description 3
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 3
- 201000000052 gastrinoma Diseases 0.000 description 3
- 230000000705 hypocalcaemia Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000021255 pancreatic insulinoma Diseases 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical class C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229960000553 somatostatin Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- LWULHXVBLMWCHO-UHFFFAOYSA-N 2-[[[5-(2,6-dimethoxyphenyl)-1-[4-[[3-(dimethylamino)propyl-methylamino]-oxomethyl]-2-propan-2-ylphenyl]-3-pyrazolyl]-oxomethyl]amino]-2-adamantanecarboxylic acid Chemical compound COC1=CC=CC(OC)=C1C1=CC(C(=O)NC2(C3CC4CC(C3)CC2C4)C(O)=O)=NN1C1=CC=C(C(=O)N(C)CCCN(C)C)C=C1C(C)C LWULHXVBLMWCHO-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000034263 Amino acid transporters Human genes 0.000 description 2
- 108050005273 Amino acid transporters Proteins 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 101100315627 Caenorhabditis elegans tyr-3 gene Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108090001085 Cholecystokinin Receptors Proteins 0.000 description 2
- 102000004859 Cholecystokinin Receptors Human genes 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010014418 Electrolyte imbalance Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102400000921 Gastrin Human genes 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010037516 PSMA-617 Proteins 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- CWGJBBRZFIPXNZ-UHFFFAOYSA-N [C-]#N.Br Chemical compound [C-]#N.Br CWGJBBRZFIPXNZ-UHFFFAOYSA-N 0.000 description 2
- 230000007950 acidosis Effects 0.000 description 2
- 208000026545 acidosis disease Diseases 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229940050528 albumin Drugs 0.000 description 2
- 230000005260 alpha ray Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 229940124301 concurrent medication Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- HKASNZKRIQURIX-BZDVOYDHSA-N ethyl (2r)-2-[2-[[(2r)-1-ethoxy-1-oxo-3-sulfanylpropan-2-yl]amino]ethylamino]-3-sulfanylpropanoate;dihydrochloride Chemical compound Cl.Cl.CCOC(=O)[C@H](CS)NCCN[C@@H](CS)C(=O)OCC HKASNZKRIQURIX-BZDVOYDHSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 2
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000001607 nephroprotective effect Effects 0.000 description 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011809 primate model Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000011362 radionuclide therapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000004926 tubular epithelial cell Anatomy 0.000 description 2
- 210000005233 tubule cell Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- JBHPLHATEXGMQR-LFWIOBPJSA-N vipivotide tetraxetan Chemical compound OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](CC1=CC=C2C=CC=CC2=C1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC1)C(O)=O)C(O)=O JBHPLHATEXGMQR-LFWIOBPJSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LFEGKCKGGNXWDV-LUOJOMRDSA-N (2S)-2-[[(1S)-1-carboxy-5-[(4-(131I)iodanylphenyl)carbamoylamino]pentyl]carbamoylamino]pentanedioic acid Chemical compound C(=O)(O)[C@H](CCCCNC(=O)NC1=CC=C(C=C1)[131I])NC(N[C@H](C(=O)O)CCC(=O)O)=O LFEGKCKGGNXWDV-LUOJOMRDSA-N 0.000 description 1
- LFEGKCKGGNXWDV-NKNRFTOXSA-N (2s)-2-[[(1s)-1-carboxy-5-[(4-iodanylphenyl)carbamoylamino]pentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)NC1=CC=C([123I])C=C1 LFEGKCKGGNXWDV-NKNRFTOXSA-N 0.000 description 1
- OXUUJYOSVPMNKP-ZANJDRPYSA-N (2s)-2-[[(1s)-1-carboxy-5-[(4-iodanylphenyl)methylamino]pentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNCC1=CC=C([123I])C=C1 OXUUJYOSVPMNKP-ZANJDRPYSA-N 0.000 description 1
- LFEGKCKGGNXWDV-KBPBESRZSA-N (2s)-2-[[(1s)-1-carboxy-5-[(4-iodophenyl)carbamoylamino]pentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)NC1=CC=C(I)C=C1 LFEGKCKGGNXWDV-KBPBESRZSA-N 0.000 description 1
- OZFJRKAKSNINHF-KKUMJFAQSA-N (2s)-2-[[[(4s)-4-[[(4s)-4-(6-aminohexanoylamino)-4-carboxybutanoyl]amino]-4-carboxybutoxy]-hydroxyphosphoryl]amino]pentanedioic acid Chemical compound NCCCCCC(=O)N[C@H](C(O)=O)CCC(=O)N[C@H](C(O)=O)CCCOP(O)(=O)N[C@H](C(O)=O)CCC(O)=O OZFJRKAKSNINHF-KKUMJFAQSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- ONJXCGCIKIYAPL-MLRSDOHDSA-K 2-[2-[[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-16-benzyl-4-[[(2r,3r)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phe Chemical compound [111In+3].C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)NC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O)C1=CC=CC=C1 ONJXCGCIKIYAPL-MLRSDOHDSA-K 0.000 description 1
- DZTVAULYUGBHSF-UHFFFAOYSA-N 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 DZTVAULYUGBHSF-UHFFFAOYSA-N 0.000 description 1
- RLSHPQZZAHLCGV-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)N1CCN(CC(O)=O)CCN(CC(O)=O)CC1 RLSHPQZZAHLCGV-UHFFFAOYSA-N 0.000 description 1
- WLCSPWJAQXJSCS-ZALMWWTDSA-K 2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-16-(naphthalen-1-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate gallium-68(3+) Chemical compound [68Ga+3].C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC2)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 WLCSPWJAQXJSCS-ZALMWWTDSA-K 0.000 description 1
- MXDPZUIOZWKRAA-PRDSJKGBSA-K 2-[4-[2-[[(2r)-1-[[(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-4-[[(1s,2r)-1-carboxy-2-hydroxypropyl]carbamoyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-y Chemical compound [177Lu+3].C([C@H](C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC1=O)C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1)C1=CC=CC=C1 MXDPZUIOZWKRAA-PRDSJKGBSA-K 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- BVIZIWVHTBDMEX-RCUQKECRSA-R 2-[bis(2-ethoxyethyl)phosphaniumyl]ethyl-bis(2-ethoxyethyl)phosphanium;dioxotechnetium-99 Chemical compound O=[99Tc]=O.CCOCC[PH+](CCOCC)CC[PH+](CCOCC)CCOCC.CCOCC[PH+](CCOCC)CC[PH+](CCOCC)CCOCC BVIZIWVHTBDMEX-RCUQKECRSA-R 0.000 description 1
- JRARHYJPRBTPIT-UHFFFAOYSA-N 2-amino-2-benzamidoacetic acid Chemical class OC(=O)C(N)NC(=O)C1=CC=CC=C1 JRARHYJPRBTPIT-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- HUHDYASLFWQVOL-WZTVWXICSA-N 3-[[2-[[3-[acetyl(methyl)amino]-2,4,6-triiodo-5-(methylcarbamoyl)benzoyl]amino]acetyl]amino]-5-(2-hydroxyethylcarbamoyl)-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I HUHDYASLFWQVOL-WZTVWXICSA-N 0.000 description 1
- QXFUBAAEKCHBQY-UHFFFAOYSA-N 3-[hydroxy(methyl)phosphoryl]propanoic acid Chemical compound CP(O)(=O)CCC(O)=O QXFUBAAEKCHBQY-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001209177 Akis Species 0.000 description 1
- 241000282709 Aotus trivirgatus Species 0.000 description 1
- 101001044245 Arabidopsis thaliana Insulin-degrading enzyme-like 1, peroxisomal Proteins 0.000 description 1
- FVBZXNSRIDVYJS-AVGNSLFASA-N Arg-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCN=C(N)N FVBZXNSRIDVYJS-AVGNSLFASA-N 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000011057 Breast sarcoma Diseases 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 101000894568 Catharanthus roseus Catharanthine synthase Proteins 0.000 description 1
- 108010078140 Cation Transport Proteins Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 102000003837 Epithelial Sodium Channels Human genes 0.000 description 1
- 108090000140 Epithelial Sodium Channels Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000010451 Folate receptor alpha Human genes 0.000 description 1
- 108050001931 Folate receptor alpha Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100032518 Gamma-crystallin B Human genes 0.000 description 1
- 101710092798 Gamma-crystallin B Proteins 0.000 description 1
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 description 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 description 1
- 101710183768 Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 101001094047 Homo sapiens Solute carrier family 22 member 10 Proteins 0.000 description 1
- 101000821902 Homo sapiens Solute carrier family 22 member 11 Proteins 0.000 description 1
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 1
- 101000713272 Homo sapiens Solute carrier family 22 member 4 Proteins 0.000 description 1
- 101001094021 Homo sapiens Solute carrier family 22 member 7 Proteins 0.000 description 1
- 101001093997 Homo sapiens Solute carrier family 22 member 8 Proteins 0.000 description 1
- 101001094053 Homo sapiens Solute carrier family 22 member 9 Proteins 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 206010020944 Hypoaldosteronism Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 208000029663 Hypophosphatemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- VLHUSFYMPUDOEL-WZTVWXICSA-N Iothalamate meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I VLHUSFYMPUDOEL-WZTVWXICSA-N 0.000 description 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 1
- UKIYDXCFKFLIMU-UHFFFAOYSA-M Isopaque Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I UKIYDXCFKFLIMU-UHFFFAOYSA-M 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 239000002879 Lewis base Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229940127049 Lutathera Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000036631 Metastatic pain Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100420517 Mus musculus Slc22a21 gene Proteins 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical class OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 102000017922 Neurotensin receptor Human genes 0.000 description 1
- 108060003370 Neurotensin receptor Proteins 0.000 description 1
- RFFFFGRYVZESLB-CXODGJKXSA-N OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)c1ccc(CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)c2ccc([18F])nc2)cc1)C(O)=O)C(O)=O Chemical compound OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](Cc1ccc2ccccc2c1)NC(=O)c1ccc(CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)c2ccc([18F])nc2)cc1)C(O)=O)C(O)=O RFFFFGRYVZESLB-CXODGJKXSA-N 0.000 description 1
- 108010089503 Organic Anion Transporters Proteins 0.000 description 1
- 102000007990 Organic Anion Transporters Human genes 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- APJPXSFJBMMOLW-KBPBESRZSA-N Phe-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 APJPXSFJBMMOLW-KBPBESRZSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FISHYTLIMUYTQY-GUBZILKMSA-N Pro-Gln-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1 FISHYTLIMUYTQY-GUBZILKMSA-N 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 108091006172 SLC21 Proteins 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108010038615 Solute Carrier Family 22 Member 5 Proteins 0.000 description 1
- 102100035282 Solute carrier family 22 member 10 Human genes 0.000 description 1
- 102100021493 Solute carrier family 22 member 11 Human genes 0.000 description 1
- 102100036929 Solute carrier family 22 member 3 Human genes 0.000 description 1
- 102100036928 Solute carrier family 22 member 4 Human genes 0.000 description 1
- 102100036924 Solute carrier family 22 member 5 Human genes 0.000 description 1
- 102100035270 Solute carrier family 22 member 7 Human genes 0.000 description 1
- 102100035227 Solute carrier family 22 member 8 Human genes 0.000 description 1
- 102100032846 Solute carrier organic anion transporter family member 1A2 Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JSTADIGKFYFAIY-GJNDDOAHSA-K [2-[bis[[hydroxy(oxido)phosphoryl]methyl]amino]ethyl-(phosphonomethyl)amino]methyl-hydroxyphosphinate;samarium-153(3+) Chemical compound [H+].[H+].[H+].[H+].[H+].[153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O JSTADIGKFYFAIY-GJNDDOAHSA-K 0.000 description 1
- OXWPSSRXRLUMOE-MCXYZKKKSA-K [Ga+3].C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2ccc(NC(N)=O)cc2)NC(=O)[C@H](Cc2ccc(NC(=O)[C@@H]3CC(=O)NC(=O)N3)cc2)NC(=O)[C@@H](CSSC[C@H](NC1=O)C(=O)N[C@H](Cc1ccc(O)cc1)C(N)=O)NC(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 Chemical compound [Ga+3].C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2ccc(NC(N)=O)cc2)NC(=O)[C@H](Cc2ccc(NC(=O)[C@@H]3CC(=O)NC(=O)N3)cc2)NC(=O)[C@@H](CSSC[C@H](NC1=O)C(=O)N[C@H](Cc1ccc(O)cc1)C(N)=O)NC(=O)[C@H](Cc1ccc(Cl)cc1)NC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 OXWPSSRXRLUMOE-MCXYZKKKSA-K 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000011420 acute papillary necrosis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- QVZZPLDJERFENQ-NKTUOASPSA-N bassianolide Chemical compound CC(C)C[C@@H]1N(C)C(=O)[C@@H](C(C)C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C(C)C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C(C)C)OC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C(C)C)OC1=O QVZZPLDJERFENQ-NKTUOASPSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002790 bombesin antagonist Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229950001178 capromab Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000003788 cerebral perfusion Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229950010726 depreotide Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 229940127043 diagnostic radiopharmaceutical Drugs 0.000 description 1
- 229960005423 diatrizoate Drugs 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229950006595 edotreotide Drugs 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012025 fluorinating agent Substances 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000046689 human FOLH1 Human genes 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229950007354 imciromab Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960004359 iodixanol Drugs 0.000 description 1
- 125000006303 iodophenyl group Chemical group 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- 229960004537 ioversol Drugs 0.000 description 1
- 229940029407 ioxaglate Drugs 0.000 description 1
- TYYBFXNZMFNZJT-UHFFFAOYSA-N ioxaglic acid Chemical compound CNC(=O)C1=C(I)C(N(C)C(C)=O)=C(I)C(C(=O)NCC(=O)NC=2C(=C(C(=O)NCCO)C(I)=C(C(O)=O)C=2I)I)=C1I TYYBFXNZMFNZJT-UHFFFAOYSA-N 0.000 description 1
- UUMLTINZBQPNGF-UHFFFAOYSA-N ioxilan Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCCO)=C(I)C(C(=O)NCC(O)CO)=C1I UUMLTINZBQPNGF-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940124280 l-arginine Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000007527 lewis bases Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 108700033205 lutetium Lu 177 dotatate Proteins 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940058213 medronate Drugs 0.000 description 1
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 231100000855 membranous nephropathy Toxicity 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
- 229960004712 metrizoic acid Drugs 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000013580 millipore water Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- IDTMSHGCAZPVLC-RYUDHWBXSA-N n-({(1r)-1-carboxy-2-[(4-fluorobenzyl)sulfanyl]ethyl}carbamoyl)-l-glutamic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CSCC1=CC=C(F)C=C1 IDTMSHGCAZPVLC-RYUDHWBXSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 102000008434 neuropeptide hormone activity proteins Human genes 0.000 description 1
- 108040002669 neuropeptide hormone activity proteins Proteins 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940127059 octreoscan Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- SZZACTGRBZTAKY-NKNBZPHVSA-F pentasodium;samarium-153(3+);n,n,n',n'-tetrakis(phosphonatomethyl)ethane-1,2-diamine Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O SZZACTGRBZTAKY-NKNBZPHVSA-F 0.000 description 1
- 238000011349 peptide receptor radionuclide therapy Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229940087876 quadramet Drugs 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 239000000718 radiation-protective agent Substances 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008060 renal absorption Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000007756 renal tubular secretion Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229950007308 satumomab Drugs 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- ZEYOIOAKZLALAP-UHFFFAOYSA-M sodium amidotrizoate Chemical compound [Na+].CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I ZEYOIOAKZLALAP-UHFFFAOYSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- UNZMYCAEMNVPHX-UHFFFAOYSA-M sodium p-aminohippurate Chemical compound [Na+].NC1=CC=C(C(=O)NCC([O-])=O)C=C1 UNZMYCAEMNVPHX-UHFFFAOYSA-M 0.000 description 1
- RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011361 targeted radionuclide therapy Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960004113 tetrofosmin Drugs 0.000 description 1
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
特に、本出願は、腎臓を損傷する可能性があるin vivo放射性標識分子、とりわけ治療用放射性医薬品の腎臓への取り込みの抑制および生体内分布の改善のための、および/または、パラアミノ馬尿酸(PAH)またはその塩もしくはカルボン酸誘導体(例えばアミノ馬尿酸ナトリウム)を使用することによって診断用放射性医薬品の場合におけるコントラストを改善するための、PAHまたはその薬学的に許容される塩もしくはカルボン酸誘導体の使用に関する。
馬尿酸の誘導体であるアミノ馬尿酸またはパラアミノ馬尿酸(PAH)は、(a)アミノ酸グリシンと(b)ヒトに天然には見出されないパラアミノ安息香酸とのアミド誘導体である。それらはアミド結合によって共有結合している。PAHのナトリウム塩、アミノ馬尿酸ナトリウムは、腎機能の診断試験、特に腎血漿流量の測定に広く使用されている診断薬である。以下において、アミノ馬尿酸、パラアミノ馬尿酸およびアミノ馬尿酸塩(特に、アルカリまたはアルカリ土類塩)、特にナトリウム塩は、同義的に使用し、「PAH」と呼ぶ。
以下に本発明を詳述するが、本発明はこれらが変化し得るので、本明細書に記載される特定の方法論、プロトコルおよび試薬に限定されないことを理解されたい。本明細書で使用される用語は、本発明の範囲を限定することを意図しておらず、添付の特許請求の範囲によってのみ限定されることも理解されたい。別途定義しない限り、本明細書で使用するすべての技術的および科学的用語は、当業者によって一般に理解されるのと同じ意味を有する。
用語「放射性核種」(または「放射性同位体」)は不安定な中性子対陽子比を有する天然または人工起源の同位体であって、粒子(すなわち、陽子(アルファ線)もしくは電子(ベータ線))または電磁放射線(ガンマ線)の発光によって崩壊する同位体を指す。言い換えれば、放射性核種は放射性崩壊を受ける。放射性医薬品の放射性標識錯体では、任意の既知の放射性核種がキレート剤によって錯化されてもよい。このような放射性核種には18F、131I、94Tc、99mTc、90In、111In、67Ga、68Ga、86Y、90Y、177Lu、161Tb、186Re、188Re、64Cu、67Cu、55Co、57Co、43Sc、44Sc、47Sc、225Ac、213Bi、212Bi、212Pb、227Th、153Sm、166Ho、152Gd、153Gd、157Gd、または166Dy、特に68Ga、177Luまたは99mTcが含まれるが、これらに限定されない。
上述のように、担体分子、例えば(癌)細胞を標的とする化合物は、好ましくは、放射性核種に配位するキレート剤に連結される。
担体分子は、例えば受容体または別の細胞(表層)分子を(腫瘍)細胞標的に結合する任意の分子であり得る。本発明の好ましい実施形態において、担体分子は、ペプチド、ペプチド模倣体、抗体断片、抗体模倣体、小分子、および結び目構造から選択される。
本発明によれば、PAHまたはその塩もしくはカルボン酸誘導体は、ソマトスタチン受容体(SSTR)を標的とする(放射性)医薬品の腎毒性副作用を低減するために好適に使用することができる。
PAHまたはその塩もしくはカルボン酸誘導体はまた、前立腺特異的膜抗原(PSMA)を標的とする(放射性)医薬品の腎毒性副作用を低減するために適切に使用され得る。
FR-αは、画像診断目的および標的療法概念のための腫瘍関連標的として最も関心を集めた。in vitroおよびin vivoでのFR陽性腫瘍細胞の標的化は、様々な治療プローブとの葉酸抱合体を使用する多くの研究グループによって例示されている。このように葉酸受容体(FR)は葉酸放射性抱合体を用いた核画像診断のための貴重な標的であることが証明されている。
PAHまたはその塩もしくはカルボン酸誘導体はまた、CCK2受容体を標的とする(放射性)医薬品の腎毒性副作用を減少させるために適切に使用され得る。
PAHまたはその塩もしくはカルボン酸誘導体はまた、インテグリンを標的とする(放射性)医薬品の腎毒性副作用を減少させるために適切に使用され得る。
〔ニューロテンシン受容体標的化合物〕
ニューロテンシン受容体1(NTR1)は、最も致死的な癌の1つである膵管腺癌において過剰発現される。SR142948AおよびSR48692などのいくつかのNTR1拮抗薬、ならびにSR142948Aに基づいて開発された177Lu標識DOTA結合NTR1拮抗薬である177Lu-3BP-2273が開発されている。これは、膵管腺癌の治療に使用されている(Baum RP et al., The Journal of Nuclear Medicine, Vol. 59, No. 5, May 2018)。
GLP-1受容体は、本質的に全ての良性インスリノーマ上に過剰発現され、ガストリノーマ上にも過剰発現される。膵臓のβ細胞から出て小さな結節として存在する良性インスリノーマはインスリンを分泌し、生命を脅かす可能性のある低血糖を引き起こす。
PAHまたはその塩もしくはカルボン酸誘導体はまた、GRP受容体を標的とする(放射性)医薬品の腎毒性副作用を減少させるために適切に使用され得る。
ニューロキニン1型受容体は、神経膠腫細胞上および腫瘍血管上で一貫して過剰発現されている(Hennig IM et al., Int J Cancer 1995; 61: 786-792)。ニューロキニン1型受容体を介して作用する放射性標識11アミノ酸ペプチド物質P(Arg Pro Lys Pro Gln Gln Phe Phe Gly Leu Met)は、悪性神経膠腫を標的とするために好適に使用することができる。特に、物質Pはキレート剤DOTAGAに結合されており、90Y標識DOTAGA物質Pは臨床試験で使用されている(Kneifel S et al., Eur J Nucl Med Mol Imaging. 2007; 34: 1388-1395。別の試験では、脳腫瘍に対する標的α放射性核種治療の実現可能性および有効性を、α線放射抱合体213Bi-DOTA-[THi8,Met(O2)11]-物質Pを使用して評価した(Cordier et al., Eur J Nucl Med Mol Imaging. 2010; 37: 1335-1344)。
PAHまたはその塩もしくはカルボン酸誘導体はまた、治療用および診断用化合物として使用される抗体模倣物の腎毒性副作用を減少させるために適切に使用され得る。
薬学的に許容される賦形剤は異なる機能的役割を示し得、限定されないが、希釈剤、充填剤、増量剤、担体、崩壊剤、結合剤、滑沢剤、流動促進剤、コーティング、溶媒および共溶媒、緩衝剤、保存剤、アジュバント、抗酸化剤、湿潤剤、消泡剤、増粘剤、甘味剤、香味剤ならびに湿潤剤を含む。
さらなる態様によれば、本発明は、本発明に従って使用される薬学的組成物、例えばパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体、上記に特定される放射性標識もしくは非放射性標識された治療用または診断用化合物、および/または本発明の薬学的組成物、を含むキットを提供する。例えば、一実施形態では、キットは、キットの一部にパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体を含むことができ、キットの別の部分に、上で特定したような本発明による薬学的組成物を含むことができ、例えばキットの別の部分に、溶解度PAHまたはその薬学的に許容される塩もしくはカルボン酸誘導体を含むことができる。溶液は等張性または高張性であってもよく、例えば任意に緩衝化された水溶液、例えばNaCl水溶液または注射用水(WFI)のように緩衝化していてもよい。本発明の別の実施形態では、キットは、キットの一部分にパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体、ならびにキットの別の部分に上記で特定されるような放射性標識および/もしくは非放射性標識された治療用または診断用化合物を含んでもよい。
さらなる態様によれば、本発明は、パラアミノ馬尿酸(PAH)もしくはその薬学的に許容される塩もしくはカルボン酸誘導体、および/または上記の薬学的組成物、ならびに/またはパラアミノ馬尿酸(PAH)もしくはその薬学的に許容される塩もしくはカルボン酸誘導体のための医薬品の調製のための上記のキット、および/または被験体における放射性標識および非放射性標識された治療用および診断用化合物の使用または腎毒性副作用の減少のための上記の薬学的組成物の使用に関する。
以下のデータは、アミノ馬尿酸ナトリウム溶液(PAH)との共投薬が、種々の担体分子、種々のキレート剤および種々の放射性核種をそれぞれ含む種々の放射性医薬品の腎臓における保持および取り込みを減少させることにおいて有意な効果を有すること、ならびに、PAH投与がリジンおよびアルギニン注入よりもはるかに有効であることを示す。さらに、PAHとの共投薬により放射性医薬品の生物学的利用能は増強され、放射性医薬品の腫瘍における取り込みは増加することが分かった。
(SPECT/CT実験:)
単一光子放射計算機トモグラフィー(SPECT)による、健常なWistarラットにおいて[177Lu-DOTA°-Tyr3]-オクトレオチドを有する腎臓保護剤当たり3動物の6グループで取得した、三次元放射性画像における関心体積(VOI)による腎臓生体分布の決定。50MBqの[177Lu-DOTA°-Tyr3]-オクトレオチドを、アミノ酸溶液(L-ArgおよびL-Lys)-注射用水中200mg/mL、パラアミノ馬尿酸ナトリウム溶液-注射用水(PAH)中200mg/mLおよび参照としてのNaCl0.9%溶液と共投与した。画像取得は、注射後0.5時間、1時間、4時間、8時間、24時間に行った。
全ての動物に、放射性トレーサー注射の10分前に、1.0mLのNaCl、Arg-LysまたはPAHを予め注射した。生体内分布のための注射溶液は、12μLの[177Lu]Lu-DOTA-TOC、1.5mLのNaClまたはArg-LysまたはPAHの混合物として調製した。
ラットに0.9%NaCl(対照)、Lys/Arg(250mg Lys/250mg Arg)およびPAH(500mg)を同時注入し、[177Lu-DOTA°-Tyr3]-オクトレオチドの腎臓への取り込みを定量的小動物SPECTにより測定した。結果を表1~3に示す。
[177Lu-DOTA°-Tyr3]-オクトレオチドのEx vivoでの器官における濃度を、上記プロトコルに従って注射後5分および60分の早期の時点で測定した。結果を図5にグラフで示す。初期の時点でさえ、[177Lu-DOTA°-Tyr3]-オクトレオチドの取り込みは、PAH注入を併用薬として使用した場合、Lys/Argと比較して、NaCl注入に対して有意に減少した(P0.005)。
画像診断研究は、別個の構造および結合足場のキレート剤によって配位された177Luまたは68Gaのいずれかで標識されたペプチドの腎臓への取り込みを減少させることにおける、PAHの有効性を評価するために設計された。放射性標識した試験化合物のトレーサー分布を、腎臓への取り込み/クリアランスおよび血液レベルに焦点を当てて、健康なWistarラットの2つの異なる集団において行った。一方の集団には、対照用の生理食塩水(MBq/kgおよびmg/kgは個別に定義される)と組み合わせて177Lu/68Ga-トレーサーを投与し、他方の集団には、最初にPAHの腹腔内注射(注射の10分前)を受けさせた後、PAH溶液の2回の静脈内注射と一緒に177Lu/68Ga-ペプチドを投与した。それぞれの177Lu/68Gaペプチド(PAHの前投与の有無にかかわらず投与)の腎クリアランスおよび全薬剤動態を、PETまたはSPECTを用いて評価した。各集団は、統計学的主題のために少なくとも3匹のラットを含む。
マウスに、環状キレート剤DOTAと結合し、治療用放射性核種ルテチウム-177:177Lu-DOTA-RGD、177Lu-DOTA-Affilin、177Lu-DOTA-Sargastrin、および177Lu-DOTA-JR11でそれぞれ放射性標識した4種類の分子を注射し、PAH(200mg/mL)または対照としての生理食塩水(0.9%塩化ナトリウム)を同時注射した。腎臓に存在する注射された放射能の割合を、上記のプロトコルに従って経時的に決定した。その結果を図6に図示する。
マウスに、環状キレート剤DOTAと結合し、治療用放射性核種ルテチウム-177:177Lu-DOTA-RGD、177Lu-DOTA-Affilin、177Lu-DOTA-Sargastrin、および177Lu-DOTA-JR11でそれぞれ放射性標識した4種類の分子を注射し、PAH(200mg/mL)または対照としての生理食塩水(0.9%塩化ナトリウム)を同時注射した。血液中に存在する注射放射能の割合を、上記のプロトコルに従って経時的に決定した。結果を図7にグラフで示す。
マウスに、非環式キレート剤HBED-CCと結合した診断68Ga標識PSMA-11を注射し、PAH(200mg/mL)または対照としての生理食塩水(0.9%NaCl)を同時注射した。腎臓(上部レーン)および血液(下部レーン)に存在する注射放射能の割合を、上記のプロトコルに従って経時的に決定した。結果を図8にグラフで示す。
ソマトスタチン受容体陽性膵腫瘍CD1ヌードマウス(AR24J)に、177Lu-DOTATOC/NaCl(Aグループ)または177Lu-DOTATOC/PAH(Bグループ)を、眼窩後静脈洞を介して静脈内注入する(Aグループ)ちょうど10分前に、50μL NaCl0.9%(Aグループ)または50μL PAH20%(Bグループ)を腹腔内注入した。公称用量レベル、濃度および容積を表6に要約する。
** 投与当日から3日間にわたる177Luの放射能減衰を考慮した濃度・線量域
マウス(1グループ3匹)をそれぞれ0.5時間、1時間、2時間、および4時間で屠殺した。器官を0.9%NaClで迅速にリンスし、乾燥させた後、秤量し、計数して、可能性のある汚染血液を排除した。その後、以下の器官/組織をサンプリングまたは採取し、秤量し、177Luについて計数した:血液、腫瘍、腎臓、肝臓、膀胱(空)、心臓、脾臓、肺、脳、筋肉、胃(内容物を含まない)、小腸(内容物を含まない)、大腸(内容物を含まない)、残留屠体。器官/組織計数からのデータを、注射投与の割合(%ID/g)として表す。NaCl0.9%中の177Lu-DOTATOCについての器官/組織分布結果(グループA)、ならびにPAHとの177Lu-DOTATOCについての器官/組織分布結果(グループB)を図9にグラフで示す。
7.1Etarfolatideの放射性標識
99mTc-Etarfolatideは、次のような化学構造を有している:
コーニングチューブ中の2gのPAHナトリウム塩を秤量;4mLのH2Oの添加;ボルテックス-PAHの部分溶解;20μLのNaOHの添加(ITGにより提供される);ボルテックス-PAHの部分溶解;20μLのNaOHの添加;ボルテックス-PAHの完全溶解;2mLのH2O、pH10の添加;80μLのHCL37%(20μLずつ)の添加、pH~6。得られた溶液の最終容量を測定し、7100μLであることが見出され、10mLのH2O中に2gのPAHの最終溶液、すなわち、200mg PAH/mLについて、2900μL(これは全て別のコーニングチューブ中にある)を添加した。0.22μMフィルターを通して濾過した後、コーニングチューブをアルミニウム箔で覆い、冷却した。
30匹のマウス(雌雄)を無作為に2群に割り当てた。
「PSMA I&T」の化学構造は以下の通りである
Claims (45)
- 被験体における放射性標識された治療用および診断用化合物ならびに非放射性標識された治療用および診断用化合物の腎毒性副作用の低減のための方法における使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- 放射性リガンド治療または診断における放射性医薬品の腎毒性副作用の低減のためにパラアミノ馬尿酸(PAH)が使用される、請求項1に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- 前記放射性医薬品が、担体分子、キレート剤および放射性核種を含む放射性核種含有抱合体分子である、請求項2に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- 前記担体分子が、ペプチド、ペプチド模倣体、抗体断片、抗体模倣体、小分子、および結び目構造から選択される、請求項3に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- 前記担体分子が、ソマトスタチン類似体、PSMA阻害剤、ガストリン類似体、インテグリン結合分子および葉酸から選択される、請求項4に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- 前記担体分子が、Tyr3-octeotride、Tyr3-octreotate、JR11、PSMA-11、Sargastrin、RGDおよび葉酸からなる群より選択される、請求項5に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- 前記キレート剤が、好ましくはDOTA、HBED-CC、NOTA、NODAGA、DOTAGA、DOTAM、TRAP、NOPO、PCTA、DFO、DTPA、DO3AP、DO3APPrA、DO3APABn、およびHYNICまたはそれらの誘導体からなる群より選択される大環状キレート剤である、請求項3~6のいずれか1項に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- 前記放射性核種が、94Tc、99mTc、90In、111In、67Ga、68Ga、86Y、90Y、177Lu、161Tb、186Re、188Re、64Cu、67Cu、55Co、57Co、43Sc、44Sc、47Sc、225Ac、213Bi、212Bi、212Pb、227Th、153Sm、166Ho、166Dy、18Fおよび131Iからなる群から選択されるか、またはDOTAによる錯化に適した放射性核種から選択され、好ましくは90In、111In、67Ga、68Ga、86Y、90Y、177Lu、161Tb、64Cu、67Cu、55Co、57Co、43Sc、44Sc、47Sc、225Ac、213Bi、212Bi、212Pb、153Sm、166Ho、225Acおよび166Dyからなる群から選択される、請求項2~7のいずれか1項に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- 前記放射性核種が、177Lu、68Ga、111In、90Y、99mTc、225Acおよび161Tb、より好ましくは177Lu、225Acおよび68Gaからなる群より選択されるか、または三価の三価の放射性核種から選択され、好ましくは177Lu、90Y、67Ga、68Ga、111In、225Ac、161Tb、44Scおよび47Scからなる群より選択される、請求項8に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- 前記放射性核種含有抱合体分子が、[177Lu-DOTA°-Tyr3]-オクトレオチド、177Lu-DOTA-JA11、177Lu-DOTA-RGD、177Lu-DOTA-Sargastrin、68Ga-HBED-CC-PSMA-11、177Lu-PSMA I&Tおよび99mTc-Etarforlatideから選択される、請求項3~9のいずれか1項に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- パラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体が、放射性標識および非放射性標識された治療用ならびに診断用化合物の腎毒性副作用を低減するさらなる物質と組み合わせて投与され、前記さらなる物質が好ましくはアミノ酸、ゼラチン、アミフォスチン、アルブミン由来ペプチド、PMPAなどのPSMA結合分子、およびビタミンから選択される、請求項1~10のいずれか1項に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- パラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体が、体重1キログラムあたり5mg~500mgの濃度で投与される、請求項1~11のいずれか1項に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- 治療用もしくは診断用化合物と、パラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体とが、1/240000~1/8000(w/w)の比率で投与される、請求項1~12のいずれか1項に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- パラアミノ馬尿酸(PAH)の薬学的に許容される塩がアミノ馬尿酸ナトリウムである、請求項1~13のいずれか1項に記載の使用のためのパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体。
- 放射性標識された薬学的化合物および/または非放射性標識された薬学的化合物ならびにパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体、ならびに薬学的に許容される賦形剤、希釈剤、担体またはそれらの組み合わせを含む薬学的組成物。
- 前記組成物が、担体分子、キレート剤および放射性核種を含む放射性核種含有抱合体分子である放射性標識薬学的化合物を含む、請求項15に記載の薬学的組成物。
- 前記担体分子が、ペプチド、ペプチド模倣体、抗体断片、抗体模倣体、小分子、および結び目構造から選択される、請求項16に記載の薬学的組成物。
- 前記担体分子が、ソマトスタチン類似体、PSMA阻害剤、ガストリン類似体、インテグリン結合分子および葉酸抱合体から選択される、請求項17に記載の薬学的組成物。
- 前記担体分子が、Tyr3-octeotride、Tyr3-octreotate、JR11、PSMA-11、Sargastrin、RGDおよび葉酸から選択される、請求項18に記載の薬学的組成物。
- 前記キレート剤が、DOTA、HBED-CC、NOTA、NODAGA、DOTAGA、DOTAM、TRAP、NOPO、PCTA、DFO、DTPA、DO3AP、DO3APPrA、DO3APABn、およびHYNICまたはそれらの誘導体から選択される、請求項16~19のいずれか1項に記載の薬学的組成物。
- 前記放射性核種が、94Tc、99mTc、90In、111In、67Ga、68Ga、86Y、90Y、177Lu、161Tb、186Re、188Re、64Cu、67Cu、55Co、57Co、43Sc、44Sc、47Sc、225Ac、213Bi、212Bi、212Pb、227Th、153Sm、166Ho、166Dy、18Fおよび131Iからなる群から選択される、請求項16~20のいずれか1項に記載の薬学的組成物。
- 前記放射性核種が、177Lu、225ACおよび68Gaから選択される、請求項21に記載の薬学的組成物。
- 前記放射性核種含有抱合体分子が、[177Lu-DOTA°-Tyr3]-オクトレオチド、177Lu-DOTA-JA11、177Lu-DOTA-RGD、177Lu-DOTA-Sargastrin、68Ga-HBED-CC-PSMA-11、177Lu-PSMA I&Tおよび99mTc-Etarforlatideから選択される、請求項16~22のいずれか1項に記載の薬学的組成物。
- 前記組成物が、PAHに加えて、放射性標識および非放射性標識された治療用ならびに診断用化合物の腎毒性副作用を低減するさらなる物質を含む、請求項15~23のいずれか1項に記載の薬学的組成物。
- PAH以外の、治療用および診断用化合物の腎毒性副作用を低減する前記薬剤が、アミノ酸、ゼラチン、アミフォスチン、アルブミン由来ペプチド、PMPAなどのPSMA結合分子、およびビタミンから選択される、請求項24に記載の薬学的組成物。
- 治療用もしくは診断用化合物およびPAHが、1/240000~1/8000(w/w)の比率で薬学的組成物中に存在する、請求項15~25のいずれか1項に記載の薬学的組成物。
- PAHの薬学的に許容される塩がアミノ馬尿酸ナトリウムである、請求項15~26のいずれか1項に記載の薬学的組成物。
- キットの1つの部分にパラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体を含み、キットの別の部分に放射性標識および/もしくは非放射性標識された治療用または診断用化合物ならびに/または請求項15~27のいずれか1項に記載の薬学的組成物をさらに含むキット。
- 被験体における放射性標識および非放射性標識された治療用ならびに診断用化合物の腎毒性副作用を低減させるための薬品の調製のための、パラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体、または請求項15~27のいずれか1項に記載の薬学的組成物、または請求項28に記載のキットの使用。
- 被験体における放射性標識および非放射性標識された治療用ならびに診断用化合物の腎毒性副作用の低減のための方法において使用するための、請求項15~27のいずれか1項に記載の組成物、または請求項28に記載のキット。
- 被験体における放射性標識および非放射性標識された治療用ならびに診断用化合物の腎毒性副作用の低減のための方法であって、放射性標識および/または非放射性標識された化合物を使用する画像診断または治療の前、間または後に、被験体に請求項15~27のいずれか1項に記載の薬学的組成物または請求項28に記載のキットを投与することを含む、方法。
- 被験体における放射性標識および非放射性標識された治療用ならびに診断用化合物の腎毒性副作用の低減のための方法であって、被験体に放射性標識もしくは非放射性標識された治療用または診断用化合物と組み合わせて、パラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体を投与することを含み、PAHの投与は、放射性標識もしくは非放射性標識された治療用または診断用化合物の投与の前および/または間および/または後、特に放射性標識もしくは非放射性標識された治療用または診断用化合物の投与の(i)前、間および後または(ii)前および後である、方法。
- 前記方法が放射性リガンド治療または診断における放射性医薬品の腎毒性副作用の低減のためのものであり、前記放射性医薬品が、担体分子、キレート剤および放射性核種を含む放射性核種含有抱合体分子である、請求項32に記載の方法。
- 前記担体分子が、ペプチド、ペプチド模倣体、小分子、および結び目構造から選択される、請求項33に記載の方法。
- 前記担体分子が、ソマトスタチン類似体、PSMA阻害剤、ガストリン類似体、インテグリン結合分子および葉酸から選択される、請求項34に記載の方法。
- 前記担体分子が、Tyr3-octeotride、Tyr3-octreotate、JR11、PSMA-11、Sargastrin、RGDおよび葉酸から選択される、請求項35に記載の方法。
- 前記キレート剤が、DOTA、HBED-CC、NOTA、NODAGA、DOTAGA、DOTAM、TRAP、NOPO、PCTA、DFO、DTPA、DO3AP、DO3APPrA、DO3APABn、およびHYNICまたはそれらの誘導体から選択される、請求項33~36のいずれか1項に記載の方法。
- 前記放射性核種が、94Tc、99mTc、90In、111In、67Ga、68Ga、86Y、90Y、177Lu、161Tb、186Re、188Re、64Cu、67Cu、55Co、57Co、43Sc、44Sc、47Sc、225Ac、213Bi、212Bi、212Pb、227Th、153Sm、166Ho、166Dy、18Fおよび131Iからなる群から選択される、請求項33から37のいずれか1項に記載の方法。
- 前記放射性核種が、177Lu、225ACおよび68Gaから選択される、請求項38に記載の方法。
- 前記放射性核種含有抱合体分子が、[177Lu-DOTA°-Tyr3]-オクトレオチド、177Lu-DOTA-JA11、177Lu-DOTA-RGD、177Lu-DOTA-Sargastrin、68Ga-HBED-CC-PSMA-11、177Lu-PSMA I&Tおよび99mTc-Etarforlatideから選択される、請求項33~39のいずれか1項に記載の方法。
- パラアミノ馬尿酸(PAH)またはその薬学的に許容される塩もしくはカルボン酸誘導体が、放射性標識および非放射性標識された治療用ならびに診断用化合物の腎毒性副作用を低減するさらなる物質と組み合わせて使用される、請求項31~40のいずれか1項に記載の方法。
- PAH以外の、放射性標識および非放射性標識された治療用ならびに診断用化合物の腎毒性副作用を低減する前記物質が、アミノ酸、ゼラチン、アミフォスチン、アルブミン由来ペプチド、PMPAなどのPSMA結合分子、およびビタミンから選択される、請求項41に記載の方法。
- PAHまたはその薬学的に許容される塩もしくはカルボン酸誘導体が、体重1キログラムあたり5mg~500mgの量で投与される、請求項31~42のいずれか1項に記載の方法。
- 治療用および/または診断用化合物ならびにPAHまたはその薬学的に許容される塩もしくはカルボン酸誘導体が、1/240000~1/8000(w/w)の比率で使用される、請求項31~43のいずれか1項に記載の方法。
- PAHの薬学的に許容される塩がアミノ馬尿酸ナトリウムである、請求項31~44のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2019/061882 | 2019-05-08 | ||
PCT/EP2019/061882 WO2020224780A1 (en) | 2019-05-08 | 2019-05-08 | Para-aminohippuric acid (pah) as a renal protective substance |
PCT/EP2020/062950 WO2020225447A1 (en) | 2019-05-08 | 2020-05-08 | Para-aminohippuric acid (pah) as a renal protective substance |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022532187A true JP2022532187A (ja) | 2022-07-13 |
JPWO2020225447A5 JPWO2020225447A5 (ja) | 2023-05-23 |
JP7436512B2 JP7436512B2 (ja) | 2024-02-21 |
Family
ID=66484050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021566582A Active JP7436512B2 (ja) | 2019-05-08 | 2020-05-08 | 腎保護物質としてのパラアミノ馬尿酸(pah) |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220304964A1 (ja) |
EP (2) | EP3965751B1 (ja) |
JP (1) | JP7436512B2 (ja) |
KR (1) | KR20220044678A (ja) |
CN (1) | CN114126654A (ja) |
AU (1) | AU2020268836B2 (ja) |
BR (1) | BR112021022200A2 (ja) |
CA (1) | CA3135331A1 (ja) |
ES (1) | ES2938721T3 (ja) |
WO (2) | WO2020224780A1 (ja) |
ZA (1) | ZA202107431B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024111404A1 (ja) * | 2022-11-21 | 2024-05-30 | 協和発酵バイオ株式会社 | 抗がん剤により誘発される急性腎障害の予防又は治療剤 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022096103A1 (en) * | 2020-11-05 | 2022-05-12 | ITM Isotopen Technologien München AG | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006199688A (ja) * | 2004-12-20 | 2006-08-03 | Santen Pharmaceut Co Ltd | 角結膜障害治療剤 |
JP2008199668A (ja) * | 2003-10-15 | 2008-08-28 | Sony Corp | 固体撮像装置、画素信号処理方法 |
US20090318330A1 (en) * | 2006-05-31 | 2009-12-24 | Marion De Jong | Combination of amino acid solution and a gelatin derivative for inhibiting renal up-take |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT373177B (de) | 1982-05-12 | 1983-12-27 | Ver Edelstahlwerke Ag | Einrichtung zur durchfuehrung von umschmelzverfahren mit selbstverzehrenden elektroden |
WO2001005383A2 (en) | 1999-07-16 | 2001-01-25 | Mallinckrodt, Inc. | Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine |
CN101472593A (zh) * | 2006-06-19 | 2009-07-01 | 索尔瓦药物有限公司 | 腺苷a1拮抗剂在放射造影介质诱发的肾病中的用途 |
PL2970345T3 (pl) | 2013-03-15 | 2019-12-31 | Cancer Targeted Technology Llc | Znakowane 18F środki do obrazowania PET ukierunkowane na PSMA |
WO2014204854A1 (en) | 2013-06-18 | 2014-12-24 | Aminomdix Inc. | Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids |
EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
JP2017530109A (ja) | 2014-09-08 | 2017-10-12 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 前立腺癌についてのpsmaを標的とした放射性核種治療中の臓器の保護 |
-
2019
- 2019-05-08 WO PCT/EP2019/061882 patent/WO2020224780A1/en active Application Filing
-
2020
- 2020-05-08 BR BR112021022200A patent/BR112021022200A2/pt not_active Application Discontinuation
- 2020-05-08 KR KR1020217036950A patent/KR20220044678A/ko unknown
- 2020-05-08 WO PCT/EP2020/062950 patent/WO2020225447A1/en unknown
- 2020-05-08 AU AU2020268836A patent/AU2020268836B2/en active Active
- 2020-05-08 ES ES20725500T patent/ES2938721T3/es active Active
- 2020-05-08 EP EP20725500.1A patent/EP3965751B1/en active Active
- 2020-05-08 JP JP2021566582A patent/JP7436512B2/ja active Active
- 2020-05-08 CA CA3135331A patent/CA3135331A1/en active Pending
- 2020-05-08 CN CN202080033785.6A patent/CN114126654A/zh active Pending
- 2020-05-08 EP EP22214592.2A patent/EP4218749A1/en not_active Withdrawn
- 2020-05-08 US US17/608,921 patent/US20220304964A1/en active Pending
-
2021
- 2021-10-01 ZA ZA2021/07431A patent/ZA202107431B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008199668A (ja) * | 2003-10-15 | 2008-08-28 | Sony Corp | 固体撮像装置、画素信号処理方法 |
JP2006199688A (ja) * | 2004-12-20 | 2006-08-03 | Santen Pharmaceut Co Ltd | 角結膜障害治療剤 |
US20090318330A1 (en) * | 2006-05-31 | 2009-12-24 | Marion De Jong | Combination of amino acid solution and a gelatin derivative for inhibiting renal up-take |
Non-Patent Citations (3)
Title |
---|
PHARMACEUTICALS, vol. 7, JPN6023023993, 2014, pages 779 - 796, ISSN: 0005082874 * |
日本薬学会年会要旨集, vol. 124, no. 3, JPN6023023996, 2004, pages 66 - 29, ISSN: 0005082872 * |
第12回金属の関与する生体関連反応シンポジウム−日々の生活と金属− 講演要旨集, JPN6023023994, 2002, pages 132 - 133, ISSN: 0005082873 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024111404A1 (ja) * | 2022-11-21 | 2024-05-30 | 協和発酵バイオ株式会社 | 抗がん剤により誘発される急性腎障害の予防又は治療剤 |
Also Published As
Publication number | Publication date |
---|---|
KR20220044678A (ko) | 2022-04-11 |
ZA202107431B (en) | 2024-02-28 |
EP3965751A1 (en) | 2022-03-16 |
JP7436512B2 (ja) | 2024-02-21 |
CA3135331A1 (en) | 2020-11-12 |
EP3965751B1 (en) | 2022-12-28 |
AU2020268836A1 (en) | 2021-10-28 |
US20220304964A1 (en) | 2022-09-29 |
EP4218749A1 (en) | 2023-08-02 |
WO2020225447A1 (en) | 2020-11-12 |
ES2938721T3 (es) | 2023-04-14 |
CN114126654A (zh) | 2022-03-01 |
BR112021022200A2 (pt) | 2022-01-04 |
WO2020224780A1 (en) | 2020-11-12 |
AU2020268836B2 (en) | 2023-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7242538B2 (ja) | 放射線治療及び画像診断のための製剤 | |
JP7436512B2 (ja) | 腎保護物質としてのパラアミノ馬尿酸(pah) | |
EP3268337B1 (en) | Methods and kits for preparing radionuclide complexes | |
Müller et al. | Single photon emission computed tomography tracer | |
EP4065176B1 (en) | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer | |
JP2023552180A (ja) | 放射性核種錯体のための安定な製剤 | |
Pietzsch et al. | Single photon emission computed tomography tracer | |
RU2804349C2 (ru) | Парааминогиппуровая кислота (паг) как вещество для защиты почек | |
US20240131206A1 (en) | Peptide receptor radionuclide therapy | |
RU2787105C2 (ru) | Новые пса-связывающие агенты и их применение | |
Mamat | Hans-Jürgen Pietzsch, Constantin Mamat, Cristina Müller, and Roger Schibli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230404 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230404 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230509 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230613 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230822 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231113 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7436512 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |